IL6 and breast cancer: These data suggest that high expression IL-6 plus PTGER2 plus PTGER4 in breast cancer could be a diagnostic biomarker for aggressive TNBC tumors (most likely of the IRISOE phenotype) that have a high propensity to metastasize and/or kill the patient.